ePrivacy and GPDR Cookie Consent by TermsFeed Generator

Detail of the clinical trial

Title of the trial A Phase 1/2 Multi-Center Study Evaluating the Safety and Efficacy of KTE-X19 in Pediatric and Adolescent Subjects with Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)P/142/2020
EudraCT number 2015-005010-30
Protocol number KTE-C19-104
Sponsor Kite Pharma, Inc., 2225 Colorado Avenue. Santa Monica, California 90404, United States of America
Indications Hemato-oncology
Diagnosis Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Population in clinical trial Children (2-11 years)
Adolescents (12-17 years)
Adults (18-65 years)
Male
Female
Patients
Year of receiving the request to Institute (SÚKL) 2021
Date of approval by Institute (SÚKL) 12. 11. 2021
Date of approval by EC
Date of initiation CT in ČR
Date of ending CT in ČR
Notice
Sites Fakultní nemocnice Brno, Klinika dětské onkologie, Jihlavská 20,Brno,625 00

‹‹ Back to list